Emerging data suggests that retatrutide, a experimental dual-action peptide agonist targeting both GLP-1 and GIP receptors, could represent a significant advance in obesity treatment therapies. Unlike existing treatments focusing solely on GLP-1 signaling, retatrutide's dual mechanism of action p